TNF and autoimmune disease: Given vincristine’s (VCR) established therapeutic efficacy in other autoimmune diseases and its theoretical capacity - disrupt TNF signaling pathways thereby inhibiting macrophage/T-cell activation/migration, reducing inflammatory cytokine production, and ultimately suppressing ICI-induced hyperimmune responses - it represents a promising candidate for clinical application.